pLX304-BCL-XL-499/500R
(Plasmid
#203575)
-
PurposeExpresses V5-tagged BCL-XL with resistance to shRNA (TRCN0000033499, TRCN0000033500) in mammalian cells.
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 203575 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepLX304
- Backbone size w/o insert (bp) 9377
- Total vector size (bp) 8428
-
Vector typeMammalian Expression, Lentiviral
-
Selectable markersBlasticidin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature30°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameBCL2L1
-
Alt nameBCL2 like 1
-
SpeciesH. sapiens (human)
-
Insert Size (bp)774
-
Mutationsilent point mutations to make resistant shRNA 499/500R (TRCN0000033499, TRCN0000033500)
-
GenBank ID598
-
Entrez GeneBCL2L1 (a.k.a. BCL-XL/S, BCL2L, BCLX, Bcl-X, PPP1R52)
- Promoter CMV
-
Tag
/ Fusion Protein
- V5-tagged (C terminal on backbone)
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer CMV-F
- 3′ sequencing primer WPRE-R (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
BCL-XL was sub-cloned, using gateway cloning, from a BCL-XL-GFP fusion construct obtained from Dr. Ruth Keri's laboratory (CCF). Silent mutations were introduced in the shRNA-recognition sequences for both sh499 and sh500 using Site-directed mutagenesis.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pLX304-BCL-XL-499/500R was a gift from Abhishek Chakraborty (Addgene plasmid # 203575 ; http://n2t.net/addgene:203575 ; RRID:Addgene_203575) -
For your References section:
A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Antiapoptotic Protein in Kidney Cancer. Grubb T, Maganti S, Krill-Burger JM, Fraser C, Stransky L, Radivoyevitch T, Sarosiek KA, Vazquez F, Kaelin WG, Chakraborty AA. Clin Cancer Res. 2022 Nov 1;28(21):4689-4701. doi: 10.1158/1078-0432.CCR-22-0669. 10.1158/1078-0432.CCR-22-0669 PubMed 35776130